ASCO GI 2023 | ASCO GI 2023 highlights
Nick Pavlakis, PhD, MBBS, FRACP, Royal North Shore Hospital, Sydney, Australia, outlines highlights from the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium, including the Phase III SUNLIGHT (NCT04737187) trial of trifluridine/tipiracil (TAS-102; Lonsurf) plus bevacizumab versus bevacizumab alone in in patients with refractory metastatic colorectal cancer (mCRC), as well as the Phase III SPOTLIGHT (NCT03504397) trial which evaluated zolbetuximab in patients with CLDN18.2-positive, HER2-negative, locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Yeah. Well, the meeting this year for me was obviously yesterday in upper gastrointestinal cancers, was reading about the claudin study, the SPOTLIGHT study, and other studies that have read out for the first time. There’s some studies this afternoon in pancreas that are reading out.
And then tomorrow I think there’s the study of Lonsurf with bevacizumab versus Lonsurf alone in colorectal cancer...
Yeah. Well, the meeting this year for me was obviously yesterday in upper gastrointestinal cancers, was reading about the claudin study, the SPOTLIGHT study, and other studies that have read out for the first time. There’s some studies this afternoon in pancreas that are reading out.
And then tomorrow I think there’s the study of Lonsurf with bevacizumab versus Lonsurf alone in colorectal cancer. So I haven’t looked at the abstracts. They’re the ones sort of, I think that stand to mind.
Nothing in neuroendocrine tumors really, but that’s going to come in the next year or two I think.
Read more...
Related Videos
